West Pharmaceutical Services Inc. (NYSE:WST) declared a quarterly dividend on Wednesday, July 15th, Zacks reports. Shareholders of record on Wednesday, July 29th will be paid a dividend of 0.16 per share by the medical instruments supplier on Wednesday, August 5th. This represents a $0.64 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Tuesday, July 28th.
West Pharmaceutical Services has increased its dividend payment by an average of 275.4% annually over the last three years and has increased its dividend every year for the last 27 years. West Pharmaceutical Services has a dividend payout ratio of 17.7% meaning its dividend is sufficiently covered by earnings. Equities analysts expect West Pharmaceutical Services to earn $4.04 per share next year, which means the company should continue to be able to cover its $0.64 annual dividend with an expected future payout ratio of 15.8%.
Shares of West Pharmaceutical Services stock opened at $233.28 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.84 and a quick ratio of 2.11. The company has a 50-day moving average of $217.10 and a 200 day moving average of $178.42. The firm has a market cap of $17.17 billion, a price-to-earnings ratio of 67.42, a PEG ratio of 7.01 and a beta of 1.13. West Pharmaceutical Services has a 1 year low of $120.12 and a 1 year high of $241.70.
West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.82 by $0.19. The company had revenue of $491.50 million during the quarter, compared to analyst estimates of $466.79 million. West Pharmaceutical Services had a net margin of 13.80% and a return on equity of 17.69%. West Pharmaceutical Services's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period last year, the business earned $0.74 EPS. On average, equities analysts anticipate that West Pharmaceutical Services will post 3.61 EPS for the current year.
Several research analysts recently issued reports on the stock. Zacks Investment Research reiterated a "buy" rating and issued a $219.00 price target on shares of West Pharmaceutical Services in a research note on Sunday, May 3rd. Bank of America upgraded shares of West Pharmaceutical Services from an "underperform" rating to a "neutral" rating and increased their price target for the stock from $145.00 to $200.00 in a research note on Friday, April 24th.
In other West Pharmaceutical Services news, VP Annette F. Favorite sold 14,192 shares of the firm's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $196.90, for a total transaction of $2,794,404.80. Following the completion of the sale, the vice president now directly owns 12,937 shares in the company, valued at approximately $2,547,295.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP George Lloyd Miller sold 1,805 shares of the firm's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $189.38, for a total transaction of $341,830.90. Following the sale, the vice president now owns 7,540 shares of the company's stock, valued at $1,427,925.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,497 shares of company stock valued at $3,236,566. 1.60% of the stock is owned by company insiders.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Recommended Story: Purposes and Functions of the Federal Reserve
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 Stocks Analysts Can't Stop Upgrading
As you know, a single upgrade from a broker probably won't be a major game changer for any single stock. But, what if there was a stock that had been upgraded by more than 10 different brokers during the last 90 days?
If ten different brokers have all upgraded a stock within the last few months and the price hasn't skyrocketed (at least, not yet), you would want to take a pretty hard look at it.
It turns out that there are actually 20 different companies that have been upgraded or had their price target increased at least ten times during the last ninety days by more than 10 different brokers. This slideshow lists those companies.
View the "20 Stocks Analysts Can't Stop Upgrading".